The US Patent and Trademark Office (USPTO) has granted a notice of allowance (NOA) to RetroSense Therapeutics' patent application No. 12/299,574 covering methods of restoring visual responses with various optogenetic compounds. The ...
Tags: RetroSense, vision restoration approaches, RetroSense Therapeutics
The US Patent and Trademark Office (USPTO) has granted notice of allowance (NOA) to Collegium Pharmaceutical's patent application NO.12/823,628 covering a tamper-resistant, extended-release opioid product. The patent entitled, ...
Tags: USPTO, NOA, Collegium Opioid Product
Horizon Pharma has announced the issuance of additional notice of allowance from the US Patent and Trademark Office for Rayos (Prednisone) delayed-release tablets. Skyepharma received the notice of allowance for US patent application ...
Tags: Horizon Pharma, Rayos, release tablets
The US Patent and Trademark Office (USPTO) has granted a notice of allowance (NOA) to Hygieia's claims related to Diabetes Insulin Guidance system (DIGS) technology. The patent covers a system which automatically optimizes a patient's ...
Tags: USPTO, NOA, Hygieia, DIGS technology
The US Patent and Trademark Office (USPTO) has granted a notice of allowance (NOA) to biopharmaceutical company Amarin for its claims related to Vascepa and FDA-approved MARINE indication. The NOA, which is issued based on patent ...
Tags: NOA, Vascepa capsules, biopharmaceutical
The US office of patents and trademarks has issued notice of allowance to Ampio Pharmaceuticals for diabetic macular edema (DME) drug Optina patent. The company has also received similar patent from the Canadian Intellectual Property ...
Tags: Ampio, allowance for DME drug, Optina patent
The US Patent and Trademark Office (USPTO) has granted a notice of allowance (NOA) to Echo Therapeutics' claimed application for its Prelude SkinPrep system and Symphony tCGM system. The claimed Patent Application No. 10/792,862 entitled ...
Tags: USPTO, NOA, application, notice of allowance, Prelude SkinPrep system
The US Patent and Trademark Office (USPTO) has granted a notice of allowance (NOA) to Sanovas' minimally invasive nested balloon catheter for localized drug delivery. The patent will protect an integral part of the company's NanoVas ...
Tags: USPTO, NOA, minimally invasive nested balloon catheter, medical product
Greyson International has received a Notice of Allowance from the US Patent and Trademark Office for its Trilexon delivery system technology. The new system technology allows active ingredients to work for a longer period of time than ...
Tags: US Patent, Trilexon Delivery System, clinical technology
Specialty pharmaceutical company Cynapsus Therapeutics has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for a patent application No. 13/445,656 that covers APL-130277. Fast-acting APL-130277 is a thin ...
Coronado Biosciences has received notice of allowance for US patent application covering CNDO-109, from the US Patent and Trademark Office (USPTO). The patent is entitled, Method for activating natural killer cells by tumor cell ...
Tags: CNDO-109, cancer cells, AML
NewLink Genetics has received a notice of allowance for a Japanese patent entitled, Antitumor Vaccination Using Allogeneic Tumor Cells Expressing Alpha (1,3)-Galactosyltransferase. The patent contains pharmaceutical composition claims ...
Tags: NewLink Genetics, galactosyltransferase, antitumor vaccination
The US Patent and Trademark Office (USPTO) has granted notice of allowance (NOA) to SkyePharma for a patent application 2012/0177734 of RAYOS (Prednisone) delayed-release tablets. The NOA covers the FDA-approved RAYOS, which uses the ...
Tags: SkyePharma, RAYOS delayed-release tablets, rheumatoid arthritis
Biotech has rceived a notice of allowance from the USPTO for a patent application covering the company's long-acting CTP-enhanced human growth hormone (hGH-CTP). Once the patent is issued, PROLOR would gain additional intellectual ...
Tags: PROLOR, CTP platform, human growth hormone
The United States Patent and Trademark Office (USPTO) has issued notice of allowance for Avanir Pharmaceuticals' patent application covering Nuedexta. The patent application entitled, Pharmaceutical Compositions Comprising ...
Tags: USPTO, patent application, nuedexta, pseudobulbar affect